Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Burkitt Lymphoma 25Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Mantle-Cell 7Leukemia, Biphenotypic, Acute 7Recurrence 6Immunoglobulin Light-chain Amyloidosis 6Vomiting 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Leukemia, Myeloid, Acute 5Carcinoma, Non-Small-Cell Lung 5Smoldering Multiple Myeloma 4Neoplasm Metastasis 4Nausea 4Leukemia 4Hodgkin Disease 4Breast Neoplasms 4Blast Crisis 4Plasmacytoma 3Ovarian Neoplasms 3Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Leukemia, Plasma Cell 3

Interventions

Lenalidomide 2Dexamethasone 2ixazomib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
POEMS Syndrome × dexamethasone 21-phosphate × Clear all
NCT02921893 2025-02-12

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Mayo Clinic

Phase EARLY_PHASE1 Completed
21 enrolled
Plasma cell

Plasmacytoma, POEMS Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡